442 related articles for article (PubMed ID: 28244291)
1. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
[TBL] [Abstract][Full Text] [Related]
2. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
3. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
4. [Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
Sato Y; Ito R; Saito T; Suto Y; Tateoka N; Onodera N; Ikeda Y; Ito E; Miyano T; Tachibana N
Rinsho Ketsueki; 1989 Nov; 30(11):1923-30. PubMed ID: 2607611
[TBL] [Abstract][Full Text] [Related]
5. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.
Buchanan GR; Rivera GK; Boyett JM; Chauvenet AR; Crist WM; Vietti TJ
Blood; 1988 Oct; 72(4):1286-92. PubMed ID: 3167209
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
[TBL] [Abstract][Full Text] [Related]
7. Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia.
Yoon JH; Park JA; Kim EK; Kang HJ; Shin HY; Ahn HS
J Korean Med Sci; 2009 Apr; 24(2):281-8. PubMed ID: 19399271
[TBL] [Abstract][Full Text] [Related]
8. Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
Feig SA; Krailo MD; Harris RE; Baum E; Holcenberg JS; Kaizer H; Steinherz L; Pendergrass TW; Saunders EF; Warkentin PL
Med Pediatr Oncol; 1992; 20(2):124-9. PubMed ID: 1734217
[TBL] [Abstract][Full Text] [Related]
9. RALLE pilot: response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children.
Saarinen-Pihkala UM; Parto K; Riikonen P; Lähteenmäki PM; Békàssy AN; Glomstein A; Möttönen M
J Pediatr Hematol Oncol; 2012 May; 34(4):263-70. PubMed ID: 22246158
[TBL] [Abstract][Full Text] [Related]
10. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
Raetz EA; Borowitz MJ; Devidas M; Linda SB; Hunger SP; Winick NJ; Camitta BM; Gaynon PS; Carroll WL
J Clin Oncol; 2008 Aug; 26(24):3971-8. PubMed ID: 18711187
[TBL] [Abstract][Full Text] [Related]
11. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Parker C; Waters R; Leighton C; Hancock J; Sutton R; Moorman AV; Ancliff P; Morgan M; Masurekar A; Goulden N; Green N; Révész T; Darbyshire P; Love S; Saha V
Lancet; 2010 Dec; 376(9757):2009-17. PubMed ID: 21131038
[TBL] [Abstract][Full Text] [Related]
12. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
Sun XF; Jiang WQ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Li YH; Zhou ZM; Zhen ZJ; Xia Y; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1687-91. PubMed ID: 15601561
[TBL] [Abstract][Full Text] [Related]
14. Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen.
Bassan R; Battista R; Viero P; Pogliani E; Rossi G; Lambertenghi-Deliliers G; Rambaldi A; D'Emilio A; Buelli M; Borleri G
Semin Oncol; 1993 Dec; 20(6 Suppl 8):39-46. PubMed ID: 7507263
[TBL] [Abstract][Full Text] [Related]
15. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Henze G; v Stackelberg A; Eckert C
Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
[TBL] [Abstract][Full Text] [Related]
16. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
17. Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse.
Hijiya N; Gajjar A; Zhang Z; Sandlund JT; Ribeiro RC; Rubnitz JE; Jeha S; Liu W; Cheng C; Raimondi SC; Behm FG; Rivera GK; Relling MV; Pui CH
Leukemia; 2004 Oct; 18(10):1581-6. PubMed ID: 15356657
[TBL] [Abstract][Full Text] [Related]
18. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
19. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
